



Fresenius Kabi
Canada Ltd.

165 Galaxy Blvd, Suite 100
Toronto, Ontario
Canada M9W 0C8
T: 905.770.3711
F: 844.513.1522
W: fresenius-kabi.ca

October 3, 2022

Cladribine, Dipyridamole, and Heparin Sodium Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that our **Cladribine Injection 1 mg/mL SD Vial 10 mL**, **Dipyridamole Injection, USP 5 mg/mL SD vial 10 mL**, and **Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 30 mL** will be placed on allocation effective **October 1, 2022**. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Date
02319918	C104010	958785	723981	Cladribine Injection 1 mg/mL SD Vial 10 mL	100% Allocation Oct. 1, 2022
02244475	C601310	921014	600262	Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL	100% Allocation Oct. 1, 2022
02264315	C504036	976295	168717	Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 30 mL	100% Allocation Oct. 1, 2022

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

George Shamsoun
Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com